Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Non-Controlling Interests (2022 - 2024)

Zentalis Pharmaceuticals has reported Income from Non-Controlling Interests over the past 3 years, most recently at -$28000.0 for Q1 2024.

  • For Q1 2024, Income from Non-Controlling Interests rose 34.88% year-over-year to -$28000.0; the TTM value through Dec 2024 reached -$28000.0, up 75.44%, while the annual FY2024 figure was -$28000.0, 75.44% up from the prior year.
  • Income from Non-Controlling Interests for Q1 2024 was -$28000.0 at Zentalis Pharmaceuticals, down from -$22000.0 in the prior quarter.
  • Over five years, Income from Non-Controlling Interests peaked at -$12000.0 in Q3 2023 and troughed at -$160000.0 in Q1 2022.
  • A 3-year average of -$49888.9 and a median of -$35000.0 in 2022 define the central range for Income from Non-Controlling Interests.
  • On a YoY basis, Income from Non-Controlling Interests climbed as much as 87.88% in 2023 and fell as far as 69.23% in 2023.
  • Year by year, Income from Non-Controlling Interests stood at -$13000.0 in 2022, then plummeted by 69.23% to -$22000.0 in 2023, then decreased by 27.27% to -$28000.0 in 2024.
  • Business Quant data shows Income from Non-Controlling Interests for ZNTL at -$28000.0 in Q1 2024, -$22000.0 in Q4 2023, and -$12000.0 in Q3 2023.